The ability of the LILRB receptor ligands to suppress the activation of immune cells creates an opportunity to design therapies for inflammatory diseases that mimic the effect of the natural LILRB/inhibitory receptor ligands to agonize the receptors and create an immunosuppressive environment. By agonizing inhibitory receptors on specific subsets of B cells, NK cells, T cells and dendritic cells these therapies can treat a broad range of autoimmune and inflammatory diseases. ImmunOs has utilized its expertise in understanding the biology of HLAs and receptor signaling to create a pipeline of autoimmune therapies that are either natural inhibitory ligands or antibodies that mimic the agonistic effect of the natural ligands.
The diagram below illustrates inhibitory receptors expressed on immune cells that createan opportunity to design therapies that mimic the ligand-mediated suppression of overactive immune cells that are typically associated with inflammatory diseases.
